Medlab Clinical (CHIA:MDC) - Stock Price, News & Analysis

MDC Stock Overview

Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia.

About the company

MDC fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue is forecast to grow 41.74% per year

Risk Analysis

Earnings are forecast to decline by an average of 44.7% per year for the next 3 years

Shares are highly illiquid

Does not have meaningful revenue (A$2M)

Does not have a meaningful market cap (A$15M)

+ 1 more risk

Medlab Clinical Limited Competitors

AdAlta

ASX:1AD

AU$14.2m

Tissue Repair

ASX:TRP

AU$13.6m

Noxopharm

ASX:NOX

AU$20.5m

Radiopharm Theranostics

ASX:RAD

AU$20.5m

Price History & Performance

Summary of all time highs, changes and price drops for Medlab Clinical
Historical stock prices
Current Share Price	AU$6.90
52 Week High	AU$13.50
52 Week Low	AU$0.086
Beta	1.1
1 Month Change	0%
3 Month Change	-0.72%
1 Year Change	-41.77%
3 Year Change	-78.10%
5 Year Change	-90.98%
Change since IPO	-76.41%

Recent updates

Shareholder Returns

	MDC	AU Biotechs	AU Market
7D	0%	-1.1%	-0.6%
1Y	-41.8%	-7.0%	5.7%

Return vs Industry: MDC underperformed the Australian Biotechs industry which returned -11.1% over the past year.

Return vs Market: MDC underperformed the Australian Market which returned -0.5% over the past year.

Price Volatility

Is MDC's price volatile compared to industry and market?
MDC volatility
MDC Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.3%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.4%
10% least volatile stocks in AU Market	3.4%

Stable Share Price: MDC has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine MDC's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2012	n/a	Sean Hall	www.medlab.co

Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery.

Medlab Clinical Limited Fundamentals Summary

How do Medlab Clinical's earnings and revenue compare to its market cap?
MDC fundamental statistics
Market cap	AU$15.07m
Earnings (TTM)	-AU$8.32m
Revenue (TTM)	AU$1.54m

9.8x

P/S Ratio

-1.8x

P/E Ratio

Is MDC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MDC income statement (TTM)
Revenue	AU$1.54m
Cost of Revenue	AU$336.29k
Gross Profit	AU$1.20m
Other Expenses	AU$9.52m
Earnings	-AU$8.32m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-3.64
Gross Margin	78.11%
Net Profit Margin	-541.67%
Debt/Equity Ratio	0%

How did MDC perform over the long term?

See historical performance and comparison

MDC Stock Overview

Rewards

Risk Analysis

Medlab Clinical Limited Competitors

ASX:1AD

AU$14.2m

ASX:TRP

AU$13.6m

ASX:NOX

AU$20.5m

ASX:RAD

AU$20.5m

Price History & Performance

Recent News & Updates

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update

Medlab Clinical Limited Provides NanaBis and NanoCBD Clinical Development Update

Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director

Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022

Recent updates

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update

Medlab Clinical Limited Provides NanaBis and NanoCBD Clinical Development Update

Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director

Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022

Medlab Clinical Ltd Announces the European Patent Office Has Formalised ACCEPTANCE of the Depression Patent, and Within the Next 2-3 Months Will Be Granted

Medlab Clinical Limited Appoints Mohit Gupta as an Independent Non-Executive Director, Effective August 8, 2022

Medlab Clinical Ltd Updates Shareholders on the Progress of Our NanoCelle NanaBis Program

Medlab Clinical Ltd Announces Update on Progression of NanoCelle NASAL COVID-19 Vaccine Program

Less than half of directors are independent

Medlab Clinical Ltd Announces Update on NanoCBDTM

Medlab Clinical Ltd Announces the Receipt of "Favorable Opinion" Status from the UK Research Ethics Committee for the Forthcoming Nanabistm Phase 3 Trial, with No Additional Conditions or Submission Required

Full year 2021 earnings released: AU$0.042 loss per share (vs AU$0.059 loss in FY 2020)

Medlab Receives Phase 3 NanaBi Trials Approval from the Australian Government, with Clinical Trials Number for Cancer Bone Pain

Australian Ethics Grants Approval for Medlab's NanaBisTM PIII Australian Sites

CFO, Company Secretary & COO has left the company

Medlab Clinical Limited announced that it expects to receive AUD 15 million in funding

Medlab Clinical Limited Appoints Cheryl Maley as an Independent Non-Executive Director

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.033 loss in 1H 2020)

Medlab Executes Australian Exclusive Non-Binding Heads of Agreement with Arrotex Australia Group Australia Pty Ltd

Medlab Clinical Limited Receives Positive Depression Trial Prelim Results

Medlab Clinical Announces US FDA Grants Investigational New Drug (IND) Status for Nanabistm

New 90-day high: AU$0.28

Medlab Clinical Provides an Update on Clinical and Pre-Clinical Programs Currently Underway

Medlab Clinical Limited Announces NanaBis Observational Study Progression Report

New 90-day high: AU$0.23

Medlab Clinical Limited Announces NanaBisTM PIII Trial Launching in the Uk with Support from the National Institute for Health Research

New 90-day high: AU$0.21

Full year earnings released - AU$0.059 loss per share

Medlab Clinical Limited has completed a Follow-on Equity Offering in the amount of AUD 1.570476 million.

Medlab Clinical Limited announced that it has received AUD 5.397603 million in funding

Shareholder Returns

Price Volatility

About the Company

Medlab Clinical Limited Fundamentals Summary

9.8x

-1.8x

Earnings & Revenue